Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 611

1.

Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.

Ren J, Catalina MD, Eden K, Liao X, Read KA, Luo X, McMillan RP, Hulver MW, Jarpe M, Bachali P, Grammer AC, Lipsky PE, Reilly CM.

Front Immunol. 2019 Oct 25;10:2512. doi: 10.3389/fimmu.2019.02512. eCollection 2019.

2.

Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.

Weißenberg SY, Szelinski F, Schrezenmeier E, Stefanski AL, Wiedemann A, Rincon-Arevalo H, Welle A, Jungmann A, Nordström K, Walter J, Imgenberg-Kreuz J, Nordmark G, Rönnblom L, Bachali P, Catalina MD, Grammer AC, Lipsky PE, Lino AC, Dörner T.

Front Immunol. 2019 Sep 24;10:2136. doi: 10.3389/fimmu.2019.02136. eCollection 2019.

3.

Role of ANA testing in the classification of patients with systemic lupus erythematosus.

Pisetsky DS, Spencer DM, Rovin B, Lipsky PE.

Ann Rheum Dis. 2019 Sep 20. pii: annrheumdis-2019-216259. doi: 10.1136/annrheumdis-2019-216259. [Epub ahead of print] No abstract available.

PMID:
31540932
4.

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.

Bursill D, Taylor WJ, Terkeltaub R, Abhishek A, So AK, Vargas-Santos AB, Gaffo AL, Rosenthal A, Tausche AK, Reginato A, Manger B, Sciré C, Pineda C, van Durme C, Lin CT, Yin C, Albert DA, Biernat-Kaluza E, Roddy E, Pascual E, Becce F, Perez-Ruiz F, Sivera F, Lioté F, Schett G, Nuki G, Filippou G, McCarthy G, da Rocha Castelar Pinheiro G, Ea HK, Tupinambá HA, Yamanaka H, Choi HK, Mackay J, ODell JR, Vázquez Mellado J, Singh JA, Fitzgerald JD, Jacobsson LTH, Joosten L, Harrold LR, Stamp L, Andrés M, Gutierrez M, Kuwabara M, Dehlin M, Janssen M, Doherty M, Hershfield MS, Pillinger M, Edwards NL, Schlesinger N, Kumar N, Slot O, Ottaviani S, Richette P, MacMullan PA, Chapman PT, Lipsky PE, Robinson P, Khanna PP, Gancheva RN, Grainger R, Johnson RJ, Te Kampe R, Keenan RT, Tedeschi SK, Kim S, Choi SJ, Fields TR, Bardin T, Uhlig T, Jansen T, Merriman T, Pascart T, Neogi T, Klück V, Louthrenoo W, Dalbeth N.

Ann Rheum Dis. 2019 Nov;78(11):1592-1600. doi: 10.1136/annrheumdis-2019-215933. Epub 2019 Sep 9.

PMID:
31501138
5.

Machine learning approaches to predict lupus disease activity from gene expression data.

Kegerreis B, Catalina MD, Bachali P, Geraci NS, Labonte AC, Zeng C, Stearrett N, Crandall KA, Lipsky PE, Grammer AC.

Sci Rep. 2019 Jul 3;9(1):9617. doi: 10.1038/s41598-019-45989-0.

6.

Dissociation Between Clinical Benefit and Persistent Urate Lowering in Patients with Chronic Refractory Gout Treated with Pegloticase.

Pillinger MH, Fields TR, Yeo AE, Lipsky PE.

J Rheumatol. 2019 Jun 15. pii: jrheum.190161. doi: 10.3899/jrheum.190161. [Epub ahead of print]

PMID:
31203212
7.

Pegloticase Treatment Significantly Decreases Blood Pressure in Patients With Chronic Gout.

Johnson RJ, Choi HK, Yeo AE, Lipsky PE.

Hypertension. 2019 Jul;74(1):95-101. doi: 10.1161/HYPERTENSIONAHA.119.12727. Epub 2019 May 13.

PMID:
31079535
8.

Response to 'Antinuclear antibodies by indirect immunofluorescence and solid phase assays' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215479. doi: 10.1136/annrheumdis-2019-215479. [Epub ahead of print] No abstract available.

PMID:
31076389
9.

Gene expression analysis delineates the potential roles of multiple interferons in systemic lupus erythematosus.

Catalina MD, Bachali P, Geraci NS, Grammer AC, Lipsky PE.

Commun Biol. 2019 Apr 23;2:140. doi: 10.1038/s42003-019-0382-x. eCollection 2019.

10.

Genomic Identification of Low-Density Granulocytes and Analysis of Their Role in the Pathogenesis of Systemic Lupus Erythematosus.

Kegerreis BJ, Catalina MD, Geraci NS, Bachali P, Lipsky PE, Grammer AC.

J Immunol. 2019 Jun 1;202(11):3309-3317. doi: 10.4049/jimmunol.1801512. Epub 2019 Apr 24.

PMID:
31019061
11.

Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase.

Lawrence Edwards N, Singh JA, Troum O, Yeo AE, Lipsky PE.

Rheumatology (Oxford). 2019 Mar 6. pii: kez017. doi: 10.1093/rheumatology/kez017. [Epub ahead of print]

PMID:
30843588
12.

Response to: 'Can solid-phase assays replace immunofluorescence for ANA screening?' by Bizzaro.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jan 18. pii: annrheumdis-2018-214829. doi: 10.1136/annrheumdis-2018-214829. [Epub ahead of print] No abstract available.

PMID:
30659048
13.

Current challenges in the development of new treatments for lupus.

Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE.

Ann Rheum Dis. 2019 Jun;78(6):729-735. doi: 10.1136/annrheumdis-2018-214530. Epub 2019 Jan 12. Review.

PMID:
30636212
14.

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.

Mandell BF, Yeo AE, Lipsky PE.

Arthritis Res Ther. 2018 Dec 29;20(1):286. doi: 10.1186/s13075-018-1782-x.

15.

Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus.

Labonte AC, Kegerreis B, Geraci NS, Bachali P, Madamanchi S, Robl R, Catalina MD, Lipsky PE, Grammer AC.

PLoS One. 2018 Dec 18;13(12):e0208132. doi: 10.1371/journal.pone.0208132. eCollection 2018.

16.

The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus.

Ren J, Panther E, Liao X, Grammer AC, Lipsky PE, Reilly CM.

Int J Mol Sci. 2018 Dec 12;19(12). pii: E4007. doi: 10.3390/ijms19124007. Review.

17.

Response to: "Antinuclear autoantibodies: discordance among four different assays" by Pacheco et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin B.

Ann Rheum Dis. 2018 Dec 1. pii: annrheumdis-2018-214766. doi: 10.1136/annrheumdis-2018-214766. [Epub ahead of print] No abstract available.

PMID:
30504443
18.

Response to: 'ANA testing in "real life"' by Infantino et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Nov 17. pii: annrheumdis-2018-214650. doi: 10.1136/annrheumdis-2018-214650. [Epub ahead of print] No abstract available.

PMID:
30448767
19.

Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Aug;78(8):e77. doi: 10.1136/annrheumdis-2018-213841. Epub 2018 Jun 23. No abstract available.

PMID:
29936440
20.

Nurse-like cells in rheumatoid arthritis: Formation of survival niches cooperating between the cell types.

Ochi T, Sawai T, Murakami K, Kamataki A, Uzuki M, Tomita T, Tsuboi H, Ochi K, Ebina K, Hirohata S, Lipsky PE.

Mod Rheumatol. 2019 May;29(3):401-405. doi: 10.1080/14397595.2018.1483305. Epub 2018 Jun 29.

PMID:
29848137
21.

Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-Related Disease.

Chen Y, Lin W, Yang H, Wang M, Zhang P, Feng R, Chen H, Peng L, Zhang X, Zhao Y, Zeng X, Zhang F, Zhang W, Lipsky PE.

Arthritis Rheumatol. 2018 Nov;70(11):1853-1865. doi: 10.1002/art.40556. Epub 2018 Aug 29.

22.

Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e51. doi: 10.1136/annrheumdis-2018-213582. Epub 2018 May 5. No abstract available.

PMID:
29730639
23.

Response to: 'Variation in antinuclear antibody detection by automated indirect immunofluorescence analysis' by van Hoovels et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e49. doi: 10.1136/annrheumdis-2018-213558. Epub 2018 May 5. No abstract available.

PMID:
29730638
24.

Response to: 'Unending story of the indirect immunofluorescence assay on HEp-2 cells: old problems and new solutions?' by Meroni et al.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 Jun;78(6):e47. doi: 10.1136/annrheumdis-2018-213537. Epub 2018 Apr 28. No abstract available.

PMID:
29705742
25.

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.

Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.

Arthritis Rheumatol. 2018 Sep;70(9):1450-1458. doi: 10.1002/art.40522. Epub 2018 Aug 3.

26.

Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study.

Zhou YZ, Zhao LD, Chen H, Zhang Y, Wang DF, Huang LF, Lv QW, Liu B, Li Z, Wei W, Li H, Liao X, Liu H, Liu X, Jin H, Wang J, Fei YY, Wu QJ, Zhang W, Shi Q, Zheng WJ, Zhang FC, Tang FL, Lipsky PE, Zhang X.

Arthritis Res Ther. 2018 Apr 10;20(1):70. doi: 10.1186/s13075-018-1563-6.

27.

Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2019 May;78(5):e34. doi: 10.1136/annrheumdis-2018-213399. Epub 2018 Mar 28. No abstract available.

PMID:
29592916
28.

Role of Antinuclear Antibody Determinations in Classification Criteria for Systemic Lupus Erythematosus: Comment on the Article by Leuchten et al.

Pisetsky DS, Lipsky PE.

Arthritis Care Res (Hoboken). 2019 May;71(5):696. doi: 10.1002/acr.23559. Epub 2019 Apr 10. No abstract available.

PMID:
29579355
29.

Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Pisetsky DS, Spencer DM, Lipsky PE, Rovin BH.

Ann Rheum Dis. 2018 Jun;77(6):911-913. doi: 10.1136/annrheumdis-2017-212599. Epub 2018 Feb 9.

PMID:
29440000
30.

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.

Calabrese LH, Kavanaugh A, Yeo AE, Lipsky PE.

Arthritis Res Ther. 2017 Aug 17;19(1):191. doi: 10.1186/s13075-017-1396-8.

31.

Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases.

Grammer AC, Lipsky PE.

Rheum Dis Clin North Am. 2017 Aug;43(3):467-480. doi: 10.1016/j.rdc.2017.04.010. Review.

PMID:
28711146
32.

Mechanisms That Shape Human Antibody Repertoire Development in Mice Transgenic for Human Ig H and L Chain Loci.

Longo NS, Rogosch T, Zemlin M, Zouali M, Lipsky PE.

J Immunol. 2017 May 15;198(10):3963-3977. doi: 10.4049/jimmunol.1700133. Epub 2017 Apr 24.

33.

Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease.

Lin W, Zhang P, Chen H, Chen Y, Yang H, Zheng W, Zhang X, Zhang F, Zhang W, Lipsky PE.

Arthritis Res Ther. 2017 Feb 10;19(1):25. doi: 10.1186/s13075-017-1231-2.

34.

New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.

Pisetsky DS, Rovin BH, Lipsky PE.

Arthritis Rheumatol. 2017 Mar;69(3):487-493. doi: 10.1002/art.40008. Review. No abstract available.

35.

Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.

Dörner T, Lipsky PE.

Nat Rev Rheumatol. 2016 Nov;12(11):645-657. doi: 10.1038/nrrheum.2016.158. Epub 2016 Oct 13. Review.

PMID:
27733759
36.

Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis.

Grammer AC, Ryals MM, Heuer SE, Robl RD, Madamanchi S, Davis LS, Lauwerys B, Catalina MD, Lipsky PE.

Lupus. 2016 Sep;25(10):1150-70. doi: 10.1177/0961203316657437. Review.

PMID:
27497259
37.

A critical review of clinical trials in systemic lupus erythematosus.

Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R.

Lupus. 2016 Sep;25(10):1122-40. doi: 10.1177/0961203316652492. Review.

38.

Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.

Fleischer SJ, Daridon C, Fleischer V, Lipsky PE, Dörner T.

Arthritis Rheumatol. 2016 May;68(5):1210-21. doi: 10.1002/art.39559.

39.

The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus.

Dörner T, Shock A, Goldenberg DM, Lipsky PE.

Autoimmun Rev. 2015 Dec;14(12):1079-86. doi: 10.1016/j.autrev.2015.07.013. Epub 2015 Jul 23. Review.

40.

Autoregulatory function of interleukin-10-producing pre-naïve B cells is defective in systemic lupus erythematosus.

Sim JH, Kim HR, Chang SH, Kim IJ, Lipsky PE, Lee J.

Arthritis Res Ther. 2015 Jul 25;17:190. doi: 10.1186/s13075-015-0687-1.

41.

Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients.

Lin W, Lu S, Chen H, Wu Q, Fei Y, Li M, Zhang X, Tian X, Zheng W, Leng X, Xu D, Wang Q, Shen M, Wang L, Li J, Wu D, Zhao L, Wu C, Yang Y, Peng L, Zhou J, Wang Y, Sha Y, Huang X, Jiao Y, Zeng X, Shi Q, Li P, Zhang S, Hu C, Deng C, Li Y, Zhang S, Liu J, Su J, Hou Y, Jiang Y, You X, Zhang H, Yan L, Zhang W, Zhao Y, Zeng X, Zhang F, Lipsky PE.

Rheumatology (Oxford). 2015 Nov;54(11):1982-90. doi: 10.1093/rheumatology/kev203. Epub 2015 Jun 22.

PMID:
26106212
42.

Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.

Fleischer SJ, Giesecke C, Mei HE, Lipsky PE, Daridon C, Dörner T.

Arthritis Rheumatol. 2014 Dec;66(12):3424-35. doi: 10.1002/art.38854.

43.

Defective PTEN regulation contributes to B cell hyperresponsiveness in systemic lupus erythematosus.

Wu XN, Ye YX, Niu JW, Li Y, Li X, You X, Chen H, Zhao LD, Zeng XF, Zhang FC, Tang FL, He W, Cao XT, Zhang X, Lipsky PE.

Sci Transl Med. 2014 Jul 23;6(246):246ra99. doi: 10.1126/scitranslmed.3009131.

44.

Response to D.M. Marcus's comment on the TRIFRA study (comparison of Tripterygium wilfordii Hook F vs methotrexate in the treatment of active rheumatoid arthritis).

Lv QW, Zhang W, Shi Q, Zheng WJ, Lipsky PE, Zhang X.

Ann Rheum Dis. 2014 Sep;73(9):e57. doi: 10.1136/annrheumdis-2014-205973. No abstract available.

PMID:
25085980
45.

TwHF versus methotrexate in the treatment of rheumatoid arthritis: response to Landewe's comment on the TRIFRA study.

Lv QW, Chen T, Zhang W, Shi Q, Zheng WJ, Lipsky PE, Zhang X.

Ann Rheum Dis. 2014 Oct;73(10):e63. doi: 10.1136/annrheumdis-2014-206156. Epub 2014 Jul 25. No abstract available.

PMID:
25063826
46.

The TRIFRA trial: efforts employed to minimise expectation bias.

Lv QW, Zhang W, Shi Q, Zheng WJ, Lipsky PE, Zhang X.

Ann Rheum Dis. 2014 Nov;73(11):e67. doi: 10.1136/annrheumdis-2014-206197. Epub 2014 Jul 23. No abstract available.

PMID:
25057182
47.

Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.

Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, Wu QJ, Jiang WL, Li HB, Gong L, Wei W, Liu H, Liu AJ, Jin HT, Wang JX, Liu XM, Li ZB, Liu B, Shen M, Wang Q, Wu XN, Liang D, Yin YF, Fei YY, Su JM, Zhao LD, Jiang Y, Li J, Tang FL, Zhang FC, Lipsky PE, Zhang X.

Ann Rheum Dis. 2015 Jun;74(6):1078-86. doi: 10.1136/annrheumdis-2013-204807. Epub 2014 Apr 14.

PMID:
24733191
48.

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.

Lipsky PE, Calabrese LH, Kavanaugh A, Sundy JS, Wright D, Wolfson M, Becker MA.

Arthritis Res Ther. 2014 Mar 4;16(2):R60. doi: 10.1186/ar4497.

49.

Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells.

Giesecke C, Frölich D, Reiter K, Mei HE, Wirries I, Kuhly R, Killig M, Glatzer T, Stölzel K, Perka C, Lipsky PE, Dörner T.

J Immunol. 2014 Apr 1;192(7):3091-100. doi: 10.4049/jimmunol.1302783. Epub 2014 Feb 24.

50.

B cells: depletion or functional modulation in rheumatic diseases.

Dörner T, Lipsky PE.

Curr Opin Rheumatol. 2014 Mar;26(2):228-36. doi: 10.1097/BOR.0000000000000000. Review.

PMID:
24126901

Supplemental Content

Loading ...
Support Center